thyroid-cancer
Novartis Wins US Approval for Targeted Cancer Drug Combination

Novartis Wins US Approval for Targeted Cancer Drug Combination

A targeted oral drug combination by Novartis won US approval for use in a wide range.

Novartis Wins US Approval for Targeted Cancer Drug Combination
IHSG
7.160,39
1.05%
74,15
LQ45
1.018,33
1.04%
10,53
USD/IDR
14.875
0,09
EMAS
995.000
0,00%